All Episodes
|
76
|
Brian Klepper

Episode 76: High-performing organizations with Brian Klepper, EVP, The Valuation Institute

Oct 18, 2019

Episode Summary

Everyone says that they are a high-performing organization, but which ones really are? Which health care organizations have proven to deliver better outcomes at lower costs? This week, John sits down with the dynamic Brian Klepper, Ph.D., executive vice president of The Valuation Institute. Brian offers examples of unusually high-performing health care organizations and the secrets to their success.

Episode Notes

CONNECT WITH US:

🌐 Visit us on the web

🌐 Follow Health Care Rounds on LinkedIn

🌐 Follow Darwin Research Group on LinkedIn

📺 Watch Health Care Rounds on YouTube

🎧 Listen on Apple Podcasts

🎧 Listen on Spotify

⚙️ Health Care Rounds is produced by Grippi Media

‍

Recommended Next

Podcast 200: How Health Systems Build Elite Clinical Leaders w/ Dr. Jonathan Stallkamp, CMO, Main Line Health
Tune In
Podcast 199: A New Blueprint for Rural Health Care w/ Natalie L. Baggio, President, Corewell Health South
Tune In
Podcast 198: Standing Strong as an Independent Health System w/ Dr. Allen Smith & Dr. Sam Ash, South Shore Health
Tune In
Podcast 197: Making Health Care Costs Simple and Transparent w/ Mark Cuban, Co-Founder, Cost Plus Drugs
Tune In
Podcast 196: Physician Leadership in a New Era of Health Care w/ Dr. Sowmya Viswanathan, Baycare
Tune In
Podcast 195: Why Primary Care Is Under Strain w/ Dr. Greg Whisman, Chief Medical Officer, CareMore Health
Tune In
Podcast 194: Why Health Care Reform Keeps Failing w/ Dr. David Shulkin
Tune In
Podcast 193: The New Model for Specialty Pharmacy w/ Jigar Thakkar, PharmD
Tune In

Recommended Content

Browse Library
INsights
February 16, 2026

Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Read More
Read More
INsights
February 9, 2026

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Read More
Read More
INsights
February 2, 2026

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Read More
Read More
Stay Aware. Stay Informed.

Subscribe to Our Take

Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.